WB, IP
H M
Endogenous
140
Rabbit IgG
#Q92854
10507
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Mouse
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Semaphorin-4D/CD100 protein.
Background
Semaphorin-4D/CD100 (Sema4D) is a disulfide-linked homodimeric type 1 transmembrane glycoprotein belonging to the class IV family of membrane bound semaphorins. The extracellular domain of Sema4D contains a cysteine-rich semaphorin-like domain, an Ig-like domain, and a PSI domain (1). Research studies have suggested that the cytoplasmic domain has a signaling function as it is phosphorylated on serine residues (2). Initial studies involving Sema4D revealed that it was implicated in axon guidance within the central nervous system through binding its high affinity receptor, plexin-B1 (3). Sema4D function has also been extensively characterized in the immune system and is the first semaphorin found to be expressed on the surface of many types of immune cells (4-6). In the immune system, CD72 serves as a low-affinity receptor for Sema4D (7) and research studies have shown that Sema4D not only regulates T-cell activation (8,9) but is also involved in the regulation of B-cell survival and differentiation (5). Many of the physiologic effects of Sema4D in the immune system are regulated by a soluble extracellular domain-containing fragment generated through proteolytic cleavage (10).
Sema4D has also been implicated in oncogenesis as research studies have demonstrated overexpression in multiple types of solid tumors (11,12). The role of Sema4D in oncogenesis, in part, has been linked to its ability to promote tumor angiogenesis (13), cell invasion (14), and immunosuppression through enhancement of myeloid derived suppressor cell function (15).
- Love, C.A. et al. (2003) Nat Struct Biol 10, 843-8.
- Elhabazi, A. et al. (1997) J Biol Chem 272, 23515-20.
- Kolodkin, A.L. et al. (1993) Cell 75, 1389-99.
- Bougeret, C. et al. (1992) J Immunol 148, 318-23.
- Hall, K.T. et al. (1996) Proc Natl Acad Sci U S A 93, 11780-5.
- Furuyama, T. et al. (1996) J Biol Chem 271, 33376-81.
- Kumanogoh, A. et al. (2000) Immunity 13, 621-31.
- Hérold, C. et al. (1995) Int Immunol 7, 1-8.
- Jiang, X. et al. (2017) Front Immunol 8, 765.
- Elhabazi, A. et al. (2001) J Immunol 166, 4341-7.
- Chen, Y. et al. (2012) Int J Mol Sci 13, 13264-74.
- Liu, H. et al. (2014) Microvasc Res 93, 1-8.
- Basile, J.R. et al. (2006) Proc Natl Acad Sci U S A 103, 9017-22.
- Kato, S. et al. (2011) Cancer Sci 102, 2029-37.
- Younis, R.H. et al. (2016) J Immunol 196, 1419-29.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.